L. Ghorbal
University of Sfax
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by L. Ghorbal.
BMC Cancer | 2014
Mourad Chaari; Ines Ayadi; A. Rousseau; Eleftheria Lefkou; Patrick Van Dreden; Fatoumata Sidibe; Hela Ketatni; Vassiliki Galea; Amir Khaterchi; Racem Bouzguenda; Mounir Frikha; L. Ghorbal; Jamel Daoud; Choumous Kallel; Martin Quinn; Joseph Gligorov; Jean Pierre Lotz; Mohamed Hatmi; Ismail Elalamy; Grigoris T. Gerotziafas
BackgroundIn breast cancer patients routine thromboprophylaxis is not recommended but individualized risk assessment is encouraged. The incorporation of hypercoagulability biomarkers could increase the sensitivity of risk assessment models (RAM) to identify patients at VTE risk. To this aim we investigated the impact of cancer-related characteristics on hypercoagulability biomarkers.MethodsThrombin generation (TG) assessed with the Thrombogramme-Thrombinoscope®, levels of platelet derived microparticles (Pd-MP) assessed with flow cytometry, procoagulant phospholid dependent clotting time (PPL-ct) measured with a clotting assay and D-Dimers (were assessed in a cohort of 62 women with breast cancer and in 30 age matched healthy women.ResultsPatients showed significantly higher TG, Pd-MP, D-Dimers levels and shortened PPL-ct compared to the controls. The PPL-ct was inversely correlated with the levels of Pd-MP, which were increased in 97% of patients. TG and D-Dimers were increased in 76% and 59% of patients respectively. In any stage of the disease TG was significantly increased as compared to the controls. There was no significant difference of TG in patients with local, regional of metastatic stage. There was no significant difference in Pd-MP or Pd-MP/PS+ between the subgroups of patients with local or regional stage of cancer. Patients with metastatic disease had significantly higher levels of Pd-MP and Pd-MP/PS+ compared to those with regional stage. The D-Dimers increased in patients with metastatic stage. In patients on chemotherapy with less than 6 months since diagnosis TG was significantly higher compared to those on chemotherapy who diagnosed in interval > 6 months. Patients with metastatic disease had significantly higher levels of Pd-MP and D-Dimers compared to those with non-metastatic disease.ConclusionIn breast cancer patients the stage, the time elapsed since the diagnosis and the administration of chemotherapy are determinants of cellular and plasma hypercoagulability. The levels and the procoagulant activity of Pd-MP are interconnected with the biological activity and the overall burden of cancer. TG reflects the procoagulant properties of both breast cancer and chemotherapy in the initial period of cancer diagnosis. Thus the weighted incorporation of the biomarkers of cellular and plasma hypercoagulabilty in RAM for VTE might improve their predictive value.
Critical Reviews in Oncology Hematology | 2012
Hamouda Boussen; L. Ghorbal; Lejri Naouel; Noureddine Bouaouina; Said Gritli; Farouk Benna; J. Daoud
Mediterranean area (MA) represents a zone of intermediate incidence (1-5/100,000) for NPC, the highest frequency being observed in North Africa (NA) where it is characterized by a bimodal age repartition due to a first adolescence peak. In MA and NA, NPC remain diagnosed at advanced stages which impact poorly on overall and disease-free survival. Its therapy in MA followed the progresses and standardisation of protocols, based on concomitant chemoradiotherapy (CCRT) alone or preceded by induction chemotherapy (ICT) in advanced (N2-3, T3-4) stages, while localized cases are managed irradiation alone. NPC overall an disease-free survival improved, due to the use of combined chemo and radiotherapy.
Cancer Radiotherapie | 2013
J. Daoud; L. Ghorbal; W. Siala; F. Elloumi; Abdelmoneem Ghorbel; M. Frikha
PURPOSE To compare therapeutic results of nasopharyngeal carcinoma between adults and children. PATIENTS AND METHODS Three hundred and seventy seven patients with nasopharyngeal carcinoma received a radiotherapy between 1993 and 2007. Sixty-nine of them were 20years old or less. Two hundred and sixty eight patients received a chemotherapy (neoadjuvant or concomitant). RESULTS Overall survival and disease-free survival at 5 years were 67 % and 59.4 % in all patients, respectively. Overall survival rates at 5 years in children and adults were 66 % and 64 %, respectively (P=0.17), disease-free survival rates at 5 years were 66 % and 57 %, respectively (P=0.17). Local failures occurred more frequently in adults than in children (1.4 % versus 14 %). However, metastatic events were frequently seen in children. Late toxicities were important in children, xerostomia was the most common one. CONCLUSION Despite locally advanced disease in children, therapeutic results were better than in adults but not statistically significant. The use of treatment combination (chemotherapy and radiotherapy) in juvenile nasopharyngeal carcinoma may explain our findings.
Reports of Practical Oncology & Radiotherapy | 2015
Mouna Kallel; Fatma Elloumi; Abdelmajid Khabir; L. Ghorbal; Souhir Chaabouni; Habib Amouri; Mounir Frikha; Jamel Daoud
PURPOSE To define epidemiological, clinical, therapeutic and prognostic factors influencing survival of breast cancer in young women younger than 35 in southern Tunisia. MATERIAL AND METHODS This is a retrospective study of 83 patients younger than 35 years and treated within tumors mammary committee of Sfax. RESULTS The mean age was 31.7 years. T2 stage, high grade with positive node tumors were frequent. Breast surgery was performed for 73 patients. Chemotherapy was neo-adjuvant, adjuvant and palliative for respectively 10, 62 and 13 patients. Radiotherapy was delivered for 65 patients with curative intent and for 8 metastatic patients. Endocrine therapy was adjuvant in 38 patients and palliative in 6 cases. The overall survival (OS) at 5 years was 66.8%. Pejorative prognostic factors in uni-variate analysis were clinical T stage (T3, T4), and the number of involved lymph nodes. CONCLUSION Despite adequate treatment, the prognosis of breast cancer in young women remains worse. Early diagnosis is necessary to promote outcome.
Cancer Radiotherapie | 2017
L. Ghorbal; F. Elloumi; W. Siala; Abdelmajid Khabir; Abdelmoneem Ghorbel; M. Frikha; J. Daoud
Cancer Radiotherapie | 2015
L. Ghorbal; W. Abid; F. Elloumi; T. Sallemi; M. Frikha; J. Daoud
Blood | 2012
Mourad Chaari; Grigoris T. Gerotziafas; Ines Ayadi; Vassiliki Galea; L. Ghorbal; Patrick Van Dreden; Aurélie Rousseau; Racem Bouzguenda; Mounir Frikha; J. Daoud; Choumous Kallel; Barry Woodhams; Ismail Elalamy
Blood | 2012
Mourad Chaari; Grigoris T. Gerotziafas; L. Ghorbal; Vassiliki Galea; Ines Ayadi; Patrick Van Dreden; Mariette Adam; Racem Bouzguenda; Mounir Frikha; J. Daoud; Choumous Kallel; Barry Woodhams; Ismail Elalamy
Cancer Radiotherapie | 2011
R. Lahmar; L. Ghorbal; F. Elloumi; W. Siala; Abdelmonem Ghorbel; M. Frikha; J. Daoud
Cancer Radiotherapie | 2011
F. Elloumi; Mohamed Ben Amor; L. Ghorbal; Abdelmoneem Ghorbel; M. Frikha; J. Daoud